356 related articles for article (PubMed ID: 3103394)
1. Dopamine agonists as primary treatment in Parkinson's disease.
Rinne UK
Adv Neurol; 1987; 45():519-23. PubMed ID: 3103394
[No Abstract] [Full Text] [Related]
2. [Optimization of the treatment of Parkinson's disease using dopamine agonists].
Rinne UK
Arch Neurobiol (Madr); 1991; 54(6):282-7. PubMed ID: 1687430
[No Abstract] [Full Text] [Related]
3. Dopamine agonists and Parkinson's disease.
Burton K; Calne DB
Clin Neurol Neurosurg; 1984; 86(3):172-7. PubMed ID: 6091965
[TBL] [Abstract][Full Text] [Related]
4. Pergolide and lisuride in advanced Parkinson's disease.
Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M
Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627
[TBL] [Abstract][Full Text] [Related]
5. Pergolide and Parkinson's disease: new preparation. No clear benefit.
Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
[TBL] [Abstract][Full Text] [Related]
6. Dopaminergic agonists in the treatment of Parkinson's disease.
Goetz CG; Diederich NJ
Neurol Clin; 1992 May; 10(2):527-40. PubMed ID: 1350052
[TBL] [Abstract][Full Text] [Related]
7. [Dopamine agonists in the therapy of parkinson syndrome].
Kapfhammer HP; Rüther E
Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
[No Abstract] [Full Text] [Related]
8. DA agonists -- ergot derivatives: bromocriptine: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S53-67. PubMed ID: 12211141
[No Abstract] [Full Text] [Related]
9. Levodopa in the treatment of Parkinson's disease: current controversies.
Gerlach M; Reichmann H; Riederer P
Mov Disord; 2005 May; 20(5):643; author reply 643-4. PubMed ID: 15732130
[No Abstract] [Full Text] [Related]
10. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
[TBL] [Abstract][Full Text] [Related]
11. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
Kondo T
J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
[TBL] [Abstract][Full Text] [Related]
12. [Oral lisuride in Parkinson's disease].
Obeso JA; Luquin MR; Martínez Lage JM
Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822
[No Abstract] [Full Text] [Related]
13. Long-lasting drug holiday in Parkinson's disease.
Bermejo F; Calandre L; Molina JA; Martinez P; De Yebenes JG
Adv Neurol; 1987; 45():503-6. PubMed ID: 3103392
[No Abstract] [Full Text] [Related]
14. Bromocriptine in Parkinson disease.
Lieberman AN; Goldstein M
Pharmacol Rev; 1985 Jun; 37(2):217-27. PubMed ID: 3901046
[TBL] [Abstract][Full Text] [Related]
15. [Use of dopamine agonists in the treatment of Parkinson's disease].
Gekht AB
Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(9):54-8. PubMed ID: 12378886
[No Abstract] [Full Text] [Related]
16. Management of levodopa failures: the use of dopamine agonists.
Lieberman AN; Gopinathan G; Neophytides A; Goldstein M
Clin Neuropharmacol; 1986; 9 Suppl 2():S9-21. PubMed ID: 3297319
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of terguride in patients with Parkinson's disease.
Suchy I; Rinne UK; Wachtel H
Adv Neurol; 1987; 45():577-81. PubMed ID: 3548267
[No Abstract] [Full Text] [Related]
18. The variability of levodopa response in Parkinson's disease: is sensitization reversible?
Jabre MG; Bejjani BP
Mov Disord; 2008 Apr; 23(6):924; author reply 925. PubMed ID: 18163452
[No Abstract] [Full Text] [Related]
19. [Therapeutic strategies in Parkinson's disease].
Shoulson I
Arch Neurobiol (Madr); 1991; 54(6):277-81. PubMed ID: 1687429
[No Abstract] [Full Text] [Related]
20. [Dopaminergic agonists in Parkinson disease].
Dubois B; Agid Y
Rev Prat; 1986 Jan; 36(5):207-14. PubMed ID: 3961400
[No Abstract] [Full Text] [Related]
[Next] [New Search]
